| Literature DB >> 27022378 |
Xiangdang Yin1, Liang Hu2, Xiaochun Wang3.
Abstract
OBJECTIVE: To evaluate the effects of thyroid cystectomy for primary hyperparathyroidism on immune function.Entities:
Keywords: Endoscopic thyroidectomy; Immune function; Primary hyperparathyroidism; Thyroid hormone
Year: 2016 PMID: 27022378 PMCID: PMC4795871 DOI: 10.12669/pjms.321.8928
Source DB: PubMed Journal: Pak J Med Sci ISSN: 1681-715X Impact factor: 1.088
Baseline data.
| Index | Treatment group (n=46) | Control group (n=46) | t or χ2 | P |
|---|---|---|---|---|
| Gender (female/male) | 26/20 | 25/21 | 0.045 | >0.05 |
| Age (year) | 48.33±5.92 | 48.24±6.09 | 0.183 | >0.05 |
| Cyst position (left/right) | 28/18 | 27/19 | 0.078 | >0.05 |
| Cyst nature (cystic mass/solid mass) | 30/16 | 31/15 | 0.098 | >0.05 |
| Disease course (year) | 2.76±0.45 | 2.77±0.56 | 0.013 | >0.05 |
| BMI (kg/m2) | 23.98±4.28 | 24.00±5.19 | 0.021 | >0.05 |
Changes of thyroid hormone levels (x±s).
| Group | Case number (n) | Before surgery | Postoperative 1st day | Postoperative 5th day |
|---|---|---|---|---|
| FT3-Treatment group | 46 | 2.86±0.45 | 2.94±0.53 | 3.17±0.45 |
| Control group | 46 | 2.87±0.38 | 2.97±0.48 | 4.09±0.56 |
| FT4-Treatment group | 46 | 12.47±1.76 | 18.09±2.98 | 15.38±2.00 |
| Control group | 46 | 12.51±2.87 | 18.16±4.22 | 18.67±3.22 |
| TSH-Treatment group | 46 | 1.98±0.74 | 0.92±0.64* | 0.84±0.55* |
| Control group | 46 | 1.99±0.67 | 0.91±0.38 | 0.93±1.23 |
Compared with the levels before surgery, P<0.05;
inter-group comparison, P<0.05.
Changes of immunological indices (x±s).
| Group | Case number (n) | Before surgery | Postoperative 1st day | Postoperative 5th day |
|---|---|---|---|---|
| NK%-Treatment group | 46 | 10.31±2.78 | 13.45±3.09 | 8.09±3.11 |
| Control group | 46 | 10.37±3.31 | 12.36±5.33 | 9.45±4.23 |
| CD3+%-Treatment group | 46 | 76.33±5.98 | 68.21±5.09 | 75.23±7.38 |
| Control group | 46 | 76.39±6.12 | 69.37±6.32 | 70.78±12.11 |
| CD4+%-Treatment group | 46 | 44.61±5.09 | 38.78±5.88 | 46.33±5.09 |
| Control group | 46 | 44.76±5.67 | 37.89±6.13 | 41.66±6.33 |
| CD8+%-Treatment group | 46 | 33.28±6.49 | 37.68±13.22 | 31.78±5.67 |
| Control group | 46 | 33.78±6.04 | 36.88±8.20 | 28.99±6.33 |
Compared with the levels before surgery, P<0.05;
inter-group comparison, P<0.05.
Changes of serum calcium and phosphorus levels (mmol/L, x±s).
| Group | Case number (n) | Before surgery | Postoperative 1st day | Postoperative 5th day |
|---|---|---|---|---|
| Serum calcium-Treatment group | 46 | 2.81±0.83 | 1.91±0.56 | 1.84±0.67 |
| Control group | 46 | 2.80±0.78 | 2.44±0.67 | 2.11±0.44 |
| Serum phosphorous-Treatment group | 46 | 0.72±0.33 | 1.00±0.38 | 1.08±0.11 |
| Control group | 46 | 0.73±0.41 | 0.88±0.42 | 0.92±0.34 |
Compared with the levels before surgery, P<0.05;
inter-group comparison, P<0.05.
Postoperative adverse reactions (n).
| Group | Case No. | Surgical site infection | Recurrent laryngeal nerve injury | Parathyroid crisis | Hematoma | Hoarseness |
|---|---|---|---|---|---|---|
| Treatment group | 46 | 1 (2.2%) | 0 (0.0%) | 0 (0.0%) | 1 (2.2%) | 1 (2.2%) |
| Control group | 46 | 5 (10.9%) | 3 (6.5%) | 4 (8.7%) | 1 (2.2%) | 4 (8.7%) |
| χ2 | 6.398 | 7.399 | 12.874 | 0.000 | 4.852 | |
| P | <0.05 | <0.05 | <0.05 | >0.05 | <0.05 |